The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment

Nicola De Bortoli, Irene Martinucci, Maria Giacchino, Corrado Blandizzi, Santino Marchi, Vincenzo Savarino, Edoardo Savarino

Research output: Contribution to journalArticle

Abstract

Introduction: Approximately 20% of the Western population is affected by gastro-esophageal reflux disease (GERD). To date, proton pump inhibitors (PPIs) represent the mainstay of GERD medical treatment. However, despite their undoubted benefit, about 40% of GERD patients display an inadequate response to these drugs. Recently, a new PPI, ilaprazole, at oral doses of 10 mg has shown higher suppression of gastric acid secretion, more prolonged plasma half-life, and similar safety compared to 20 mg omeprazole. Areas covered: This review provides an update on the following points: pharmacokinetic profile and metabolism of ilaprazole in relation to its pharmacodynamic properties; comparative data on the pharmacokinetics and pharmacodynamics of ilaprazole with currently available PPIs; and implications for studies on the therapeutic efficacy of ilaprazole in GERD. Expert opinion: Different studies show that ilaprazole, a benzimidazole derivative, has an extended plasma half-life in comparison with all other approved PPIs. In addition, ilaprazole metabolism is not significantly influenced by CYP2C19, compared to the available PPIs. Furthermore, the pharmacological characteristics of ilaprazole confer theoretical advantages that are expected to translate into an improved acid control, particularly at night time. However, studies comparing the clinical pharmacokinetics and pharmacodynamics of ilaprazole with those of second-generation PPIs are insufficient. Moreover, further investigations assessing the efficacy of ilaprazole in the management of GERD are required. In healthy volunteers, as well as in patients with gastric or duodenal ulcers, ilaprazole has not shown clinically relevant changes in hematology and biochemistry testing, nor significant treatment-related adverse symptoms.

Original languageEnglish
Pages (from-to)1361-1369
Number of pages9
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume9
Issue number10
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Pharmacokinetics
Gastroesophageal Reflux
Esophageal Diseases
Proton Pump Inhibitors
Pharmacodynamics
Therapeutics
Metabolism
Half-Life
ilaprazole
Plasmas
Biochemistry
Acids
Omeprazole
Gastric Acid
Expert Testimony
Hematology
Stomach Ulcer
Duodenal Ulcer
Healthy Volunteers
Pharmacology

Keywords

  • Gastro-esophageal reflux disease
  • GERD
  • Ilaprazole
  • Pharmacokinetics
  • PPI

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

De Bortoli, N., Martinucci, I., Giacchino, M., Blandizzi, C., Marchi, S., Savarino, V., & Savarino, E. (2013). The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment. Expert Opinion on Drug Metabolism and Toxicology, 9(10), 1361-1369. https://doi.org/10.1517/17425255.2013.813018

The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment. / De Bortoli, Nicola; Martinucci, Irene; Giacchino, Maria; Blandizzi, Corrado; Marchi, Santino; Savarino, Vincenzo; Savarino, Edoardo.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, No. 10, 10.2013, p. 1361-1369.

Research output: Contribution to journalArticle

De Bortoli, N, Martinucci, I, Giacchino, M, Blandizzi, C, Marchi, S, Savarino, V & Savarino, E 2013, 'The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment', Expert Opinion on Drug Metabolism and Toxicology, vol. 9, no. 10, pp. 1361-1369. https://doi.org/10.1517/17425255.2013.813018
De Bortoli N, Martinucci I, Giacchino M, Blandizzi C, Marchi S, Savarino V et al. The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment. Expert Opinion on Drug Metabolism and Toxicology. 2013 Oct;9(10):1361-1369. https://doi.org/10.1517/17425255.2013.813018
De Bortoli, Nicola ; Martinucci, Irene ; Giacchino, Maria ; Blandizzi, Corrado ; Marchi, Santino ; Savarino, Vincenzo ; Savarino, Edoardo. / The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment. In: Expert Opinion on Drug Metabolism and Toxicology. 2013 ; Vol. 9, No. 10. pp. 1361-1369.
@article{c6935916e796462d9511a80f043bf082,
title = "The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment",
abstract = "Introduction: Approximately 20{\%} of the Western population is affected by gastro-esophageal reflux disease (GERD). To date, proton pump inhibitors (PPIs) represent the mainstay of GERD medical treatment. However, despite their undoubted benefit, about 40{\%} of GERD patients display an inadequate response to these drugs. Recently, a new PPI, ilaprazole, at oral doses of 10 mg has shown higher suppression of gastric acid secretion, more prolonged plasma half-life, and similar safety compared to 20 mg omeprazole. Areas covered: This review provides an update on the following points: pharmacokinetic profile and metabolism of ilaprazole in relation to its pharmacodynamic properties; comparative data on the pharmacokinetics and pharmacodynamics of ilaprazole with currently available PPIs; and implications for studies on the therapeutic efficacy of ilaprazole in GERD. Expert opinion: Different studies show that ilaprazole, a benzimidazole derivative, has an extended plasma half-life in comparison with all other approved PPIs. In addition, ilaprazole metabolism is not significantly influenced by CYP2C19, compared to the available PPIs. Furthermore, the pharmacological characteristics of ilaprazole confer theoretical advantages that are expected to translate into an improved acid control, particularly at night time. However, studies comparing the clinical pharmacokinetics and pharmacodynamics of ilaprazole with those of second-generation PPIs are insufficient. Moreover, further investigations assessing the efficacy of ilaprazole in the management of GERD are required. In healthy volunteers, as well as in patients with gastric or duodenal ulcers, ilaprazole has not shown clinically relevant changes in hematology and biochemistry testing, nor significant treatment-related adverse symptoms.",
keywords = "Gastro-esophageal reflux disease, GERD, Ilaprazole, Pharmacokinetics, PPI",
author = "{De Bortoli}, Nicola and Irene Martinucci and Maria Giacchino and Corrado Blandizzi and Santino Marchi and Vincenzo Savarino and Edoardo Savarino",
year = "2013",
month = "10",
doi = "10.1517/17425255.2013.813018",
language = "English",
volume = "9",
pages = "1361--1369",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Taylor and Francis Ltd.",
number = "10",

}

TY - JOUR

T1 - The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment

AU - De Bortoli, Nicola

AU - Martinucci, Irene

AU - Giacchino, Maria

AU - Blandizzi, Corrado

AU - Marchi, Santino

AU - Savarino, Vincenzo

AU - Savarino, Edoardo

PY - 2013/10

Y1 - 2013/10

N2 - Introduction: Approximately 20% of the Western population is affected by gastro-esophageal reflux disease (GERD). To date, proton pump inhibitors (PPIs) represent the mainstay of GERD medical treatment. However, despite their undoubted benefit, about 40% of GERD patients display an inadequate response to these drugs. Recently, a new PPI, ilaprazole, at oral doses of 10 mg has shown higher suppression of gastric acid secretion, more prolonged plasma half-life, and similar safety compared to 20 mg omeprazole. Areas covered: This review provides an update on the following points: pharmacokinetic profile and metabolism of ilaprazole in relation to its pharmacodynamic properties; comparative data on the pharmacokinetics and pharmacodynamics of ilaprazole with currently available PPIs; and implications for studies on the therapeutic efficacy of ilaprazole in GERD. Expert opinion: Different studies show that ilaprazole, a benzimidazole derivative, has an extended plasma half-life in comparison with all other approved PPIs. In addition, ilaprazole metabolism is not significantly influenced by CYP2C19, compared to the available PPIs. Furthermore, the pharmacological characteristics of ilaprazole confer theoretical advantages that are expected to translate into an improved acid control, particularly at night time. However, studies comparing the clinical pharmacokinetics and pharmacodynamics of ilaprazole with those of second-generation PPIs are insufficient. Moreover, further investigations assessing the efficacy of ilaprazole in the management of GERD are required. In healthy volunteers, as well as in patients with gastric or duodenal ulcers, ilaprazole has not shown clinically relevant changes in hematology and biochemistry testing, nor significant treatment-related adverse symptoms.

AB - Introduction: Approximately 20% of the Western population is affected by gastro-esophageal reflux disease (GERD). To date, proton pump inhibitors (PPIs) represent the mainstay of GERD medical treatment. However, despite their undoubted benefit, about 40% of GERD patients display an inadequate response to these drugs. Recently, a new PPI, ilaprazole, at oral doses of 10 mg has shown higher suppression of gastric acid secretion, more prolonged plasma half-life, and similar safety compared to 20 mg omeprazole. Areas covered: This review provides an update on the following points: pharmacokinetic profile and metabolism of ilaprazole in relation to its pharmacodynamic properties; comparative data on the pharmacokinetics and pharmacodynamics of ilaprazole with currently available PPIs; and implications for studies on the therapeutic efficacy of ilaprazole in GERD. Expert opinion: Different studies show that ilaprazole, a benzimidazole derivative, has an extended plasma half-life in comparison with all other approved PPIs. In addition, ilaprazole metabolism is not significantly influenced by CYP2C19, compared to the available PPIs. Furthermore, the pharmacological characteristics of ilaprazole confer theoretical advantages that are expected to translate into an improved acid control, particularly at night time. However, studies comparing the clinical pharmacokinetics and pharmacodynamics of ilaprazole with those of second-generation PPIs are insufficient. Moreover, further investigations assessing the efficacy of ilaprazole in the management of GERD are required. In healthy volunteers, as well as in patients with gastric or duodenal ulcers, ilaprazole has not shown clinically relevant changes in hematology and biochemistry testing, nor significant treatment-related adverse symptoms.

KW - Gastro-esophageal reflux disease

KW - GERD

KW - Ilaprazole

KW - Pharmacokinetics

KW - PPI

UR - http://www.scopus.com/inward/record.url?scp=84884224885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884224885&partnerID=8YFLogxK

U2 - 10.1517/17425255.2013.813018

DO - 10.1517/17425255.2013.813018

M3 - Article

C2 - 23802731

AN - SCOPUS:84884224885

VL - 9

SP - 1361

EP - 1369

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 10

ER -